VERVIEW

GHRP‑2 (5 mg × 10) and Ipamorelin (5 mg × 10) is a research peptide combination designed to stimulate endogenous growth hormone (GH) release through complementary mechanisms. GHRP‑2 is a synthetic growth hormone-releasing peptide (GHRP) that activates the ghrelin receptor (GHS‑R1a), increasing pulsatile GH secretion and boosting levels of insulin-like growth factor‑1 (IGF‑1). Ipamorelin is another GHRP that selectively stimulates GH release with minimal impact on cortisol, prolactin, or appetite, making it a more targeted approach in laboratory studies. When combined, GHRP‑2 and Ipamorelin engage the ghrelin receptor in a synergistic manner, potentially enhancing GH pulse amplitude and supporting downstream anabolic and regenerative pathways in preclinical models. Researchers use this blend to investigate metabolic regulation, tissue repair, and the somatotropic axis in controlled laboratory or experimental settings, providing insights into hormone signaling and growth-related physiology.

Despite scientific interest, this peptide combination is not approved by the U.S. Food and Drug Administration for therapeutic use in humans. Most supporting data come from animal studies, in vitro experiments, or small research trials, and there is limited information on human safety, efficacy, or dosing. Products containing GHRP‑2 and Ipamorelin are typically labeled for research use only and are not manufactured to pharmaceutical-grade standards. Self-administration outside controlled research settings carries potential health, safety, and ethical risks. Individuals interested in growth hormone modulation or tissue repair should consult qualified healthcare professionals and rely on evidence-based treatments rather than unregulated peptide compounds.